病毒学
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
复制(统计)
极限(数学)
2019年冠状病毒病(COVID-19)
病毒复制
2019-20冠状病毒爆发
生物
病毒
医学
数学
传染病(医学专业)
爆发
数学分析
病理
疾病
作者
María González-Orozco,Tseng Hsiang-Chi,Adam Hage,Hongjie Xia,P. Behera,Kazi Afreen,Yoatzin Peñaflor-Téllez,María I. Giraldo,Matthew B. Huante,Lucinda Puebla-Clark,Sarah van Tol,Abby Odle,Matthew Crown,Natália Teruel,Thomas R. Shelite,Vineet D. Menachery,Mark Endsley,Janice J. Endsley,Rafaël Najmanovich,Matthew Bashton
出处
期刊:
[Cold Spring Harbor Laboratory]
日期:2024-06-17
被引量:2
标识
DOI:10.1101/2024.06.17.599107
摘要
Abstract SARS-CoV-2 is a highly transmissible virus that causes COVID-19 disease. Mechanisms of viral pathogenesis include excessive inflammation and viral-induced cell death, resulting in tissue damage. We identified the host E3-ubiquitin ligase TRIM7 as an inhibitor of apoptosis and SARS-CoV-2 replication via ubiquitination of the viral membrane (M) protein. Trim7 -/- mice exhibited increased pathology and virus titers associated with epithelial apoptosis and dysregulated immune responses. Mechanistically, TRIM7 ubiquitinates M on K14, which protects cells from cell death. Longitudinal SARS-CoV-2 sequence analysis from infected patients revealed that mutations on M-K14 appeared in circulating variants during the pandemic. The relevance of these mutations was tested in a mouse model. A recombinant M- K14/K15R virus showed reduced viral replication, consistent with the role of K15 in virus assembly, and increased levels of apoptosis associated with the loss of ubiquitination on K14. TRIM7 antiviral activity requires caspase-6 inhibition, linking apoptosis with viral replication and pathology.
科研通智能强力驱动
Strongly Powered by AbleSci AI